Asia Deal Watch: Everest Licenses Asia Rights To Calliditas’ IgA Nephropathy Candidate

IgA Glomerulonephritis Illustration
IgA nephropathy is far more prevalent in China than in the US or Europe

More from Strategy

More from Business